Navigation Links
Global Bone Cement and Accessories Market Is Set to Expand from $630 Million in 2013 to Over $1 Billion by 2022
Date:9/3/2014

BURLINGTON, Mass., Sept. 3, 2014 /PRNewswire/ -- Decision Resources Group finds that the global market for bone cement and accessories will expand from $630 million in 2013 to over $1 billion by 2022. While the United States will continue to be the largest contributor of global revenues, the most growth will come from the rapidly expanding Brazilian, Indian and Chinese markets, where joint reconstruction volumes are increasing quickly and thus boosting demand for bone cement and accessories.

Other key findings from Decision Resources Group's coverage of the global bone cement and accessories market:

  • Impact of cementless implants: Although the bone cement market will be hampered by the use of cementless implants, the once rapid shift to cementless devices has slowed. Recent budget and reimbursement cuts have caused physicians to question whether the benefits of cementless implants justify their higher cost over cemented implants.
  • Premium-priced products: Despite pricing pressures, some higher-priced bone cement and accessory products will be increasingly adopted. For example, more expensive antibiotic bone cement is gaining popularity due to its ability to reduce the potential for infection. Higher-priced compatible and enclosed vacuum systems are also being adopted because they minimize the amount of monomer fumes in the operating room and reduce cement porosity.
  • Antibiotic bone cement in Japan: In 2014, the first antibiotic bone cement products—from Stryker and Biomet—entered the Japanese market, which will have a favorable impact on revenue growth. However, use of the products will be limited because they are only approved for very specific indications in Japan and there is a lack of awareness of antibiotic bone cement in the country.

Comments from Decision Resources Group Lead Analyst Deanna Edmunds:

  • "Stryker continues to lead the global market for bone cement and accessories, and the top players are all larger multinational companies that also sell related products, specifically reconstructive joint implants."
  • "The competitive landscape could see some change going forward. Zimmer's pending acquisition of Biomet could boost the combined company's position in the reconstructive implant space, which would have a positive impact on its position in the market for bone cement and accessories."

Additional Resources:

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:
Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresourcesgroup.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO


'/>"/>
SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Cambrex To Present At Rodman & Renshaw 16th Annual Global Investment Conference
2. CytoSorbents to Present at the 2014 Rodman & Renshaw Annual Global Investment Conference
3. Isis Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
4. RXi Pharmaceuticals to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
5. Relmada Therapeutics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014
6. Infinity And AbbVie Announce Global Strategic Collaboration To Develop And Commercialize Duvelisib (IPI-145) In Oncology
7. Global Markets and Technologies for Molecular Imaging Devices
8. Bariatric Surgery: Global Markets for Services and Devices
9. Acute Heart Failure Global Clinical Trials Review, H2, 2014
10. Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden
11. Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Research and Markets has announced the addition of the "Global ... ... market to grow at a CAGR of 6.83% during the period ... growth prospects of the global travel vaccines market for 2016-2020. To ... the sales of various vaccines administered to actively immunize meningococcal disease, ...
(Date:12/9/2016)... 2016  Axovant Sciences Ltd. (NYSE: ... on the treatment of dementia, today announced a ... 2b trial evaluating treatment with intepirdine (RVT-101), combined ... plus placebo in people with mild-to-moderate Alzheimer,s disease. ... to treatment was associated with reduced progression in ...
(Date:12/8/2016)... , Dec. 8, 2016 IRIDEX Corporation (NASDAQ: ... newly issued shares of common stock, $0.01 par value (the ... underwritten public offering.  The final terms of the Offering will ... pricing, and there can be no assurance as to whether ... expects to use the net proceeds it will receive from ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider of ... a new solution for Emergency Departments (ED) has been added to their portfolio. ... Department examination rooms, and with a simplified pallet of information available to the ...
(Date:12/8/2016)... ... 2016 , ... The West Virginia Medical Institute (WVMI) announced ... name change aligns the entire company with its existing Quality Insights branded projects ... are very proud of the achievements associated with the West Virginia Medical Institute ...
(Date:12/8/2016)... Pennsylvania (PRWEB) , ... December 08, 2016 , ... ... Duck Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which ... , “This was our first franchise-wide Quack Gives Back initiative, ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... offering Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has ... general counsel and Eric Hoessel to vice president of sales. , Litsinger ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick ... West, Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is ... Sciences & Medical Technology Group have been featured speakers at every DeviceTalks conference since ...
Breaking Medicine News(10 mins):